CA2708753C - Peptide servant d'agent diagnostique pour deceler la maladie de lyme - Google Patents

Peptide servant d'agent diagnostique pour deceler la maladie de lyme Download PDF

Info

Publication number
CA2708753C
CA2708753C CA2708753A CA2708753A CA2708753C CA 2708753 C CA2708753 C CA 2708753C CA 2708753 A CA2708753 A CA 2708753A CA 2708753 A CA2708753 A CA 2708753A CA 2708753 C CA2708753 C CA 2708753C
Authority
CA
Canada
Prior art keywords
peptide
seq
peptides
antibody
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2708753A
Other languages
English (en)
Other versions
CA2708753A1 (fr
Inventor
Raymond J. Dattwyler
Maria J. Gomes-Solecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biopeptides Corp
Original Assignee
Biopeptides Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopeptides Corp filed Critical Biopeptides Corp
Priority to CA2708753A priority Critical patent/CA2708753C/fr
Publication of CA2708753A1 publication Critical patent/CA2708753A1/fr
Application granted granted Critical
Publication of CA2708753C publication Critical patent/CA2708753C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne, par exemple, un peptide isolé qui comprend la série MKKNDQI(V ou G)AAIALRGVA (SEQ ID NO:64), où le peptide n'est pas plus long que 24 acides aminés et où le peptide peut se lier précisément à un anticorps introduit par un agent causal de la maladie de Lyme (une Borrelia pathologique), par exemple dans un échantillon prélevé d'un sujet atteint de la maladie de Lyme. Des versions de ce peptide comprennent, par exemple, la série MKKNDQIVAAIALRGVA (SEQ ID NO:65) ou MKKNDQIGAAIALRGVA (SEQ ID NO:66). Des peptides multimères linéaires sont également décrits et contiennent le peptide représenté par SEQ ID NO:64 ainsi qu'un épitope de peptide supplémentaire, ou plus, issu d'autres protéines de Borrelia qui peuvent également se lier précisément à un anticorps ci-dessus. Les compositions et les trousses de diagnostic qui comprennent un peptide ce cette invention sont décrites, tout comme les analyses diagnostiques qui utilisent le ou les peptides.
CA2708753A 2010-06-25 2010-06-25 Peptide servant d'agent diagnostique pour deceler la maladie de lyme Active CA2708753C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2708753A CA2708753C (fr) 2010-06-25 2010-06-25 Peptide servant d'agent diagnostique pour deceler la maladie de lyme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2708753A CA2708753C (fr) 2010-06-25 2010-06-25 Peptide servant d'agent diagnostique pour deceler la maladie de lyme

Publications (2)

Publication Number Publication Date
CA2708753A1 CA2708753A1 (fr) 2011-12-25
CA2708753C true CA2708753C (fr) 2014-02-18

Family

ID=45421237

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708753A Active CA2708753C (fr) 2010-06-25 2010-06-25 Peptide servant d'agent diagnostique pour deceler la maladie de lyme

Country Status (1)

Country Link
CA (1) CA2708753C (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116668A2 (fr) 2012-02-01 2013-08-08 Biopeptides Corp Peptides diagnostiques pour la maladie de lyme
EP3077409B1 (fr) * 2013-12-06 2020-04-01 Biopeptides Corporation Peptides destinés au diagnostic de la maladie de lyme
WO2017062535A2 (fr) 2015-10-06 2017-04-13 Bio-Rad Laboratories, Inc. Dosages immunologiques de borrelia et matériaux associés
WO2019074343A1 (fr) * 2017-10-13 2019-04-18 주식회사 나이벡 Peptide dérivé de grp78 permettant l'identification de cellules souches à haut rendement

Also Published As

Publication number Publication date
CA2708753A1 (fr) 2011-12-25

Similar Documents

Publication Publication Date Title
US7887815B2 (en) Peptide diagnostic agent for lyme disease
US11573227B2 (en) Peptides and methods for the detection of Lyme disease antibodies
CA2781110C (fr) Peptides et procedes pour la detection d'anticorps contre la maladie de lyme
EP2809348B1 (fr) Peptides diagnostiques pour la maladie de lyme
US8313915B2 (en) Early detection of canine lyme disease by specific peptides and antibodies
CA2708753C (fr) Peptide servant d'agent diagnostique pour deceler la maladie de lyme
US20150276739A1 (en) Soluble treponema pallidum protein tp0453, tp0453-tp0326 fusion protein, and use in syphilis diagnosis
EP3077409B1 (fr) Peptides destinés au diagnostic de la maladie de lyme
WO2010132758A2 (fr) Test de diagnostic à base de ospc pour la maladie de lyme
US8338566B2 (en) Characterization of BBK07 antigen of Borrelia burgdorferi and methods of use

Legal Events

Date Code Title Description
EEER Examination request